Navigation Links
MEM in Medical Technology

Memory Pharmaceuticals Achieves Enrollment Goal for Phase 2 Study of MEM 3454 in Cognitive Impairment Associated With Schizophrenia

-Triggers $5 Million Payment from Roche- MONTVALE, N.J., Nov. 19 /PRNewswire-FirstCall/ -- Memory Pharmaceuticals Corp. (Nasdaq: MEMY ) today announced that it has achieved the enrollment goal for its Phase 2 trial of R3487/MEM 3454, its lead alpha-7 nicotinic receptor agonist, in cogni...

Roche Exercises its Option to Further Develop and Commercialize Memory Pharmaceuticals' Nicotinic Alpha-7 Agonist, MEM 3454

-Memory Receives $6 Million Milestone Payment- -Memory to Host Conference Call at 9:00 a.m. EDT Today- MONTVALE, N.J. and BASEL, Switzerland, May 2 /PRNewswire-FirstCall/ -- Memory Pharmaceuticals Corp. (Nasdaq: MEMY ) and Roche (SWX: ROG) today announced that Roche has ex...

Memory Pharmaceuticals & Roche Expand Development Program for MEM 3454 in Schizophrenia

- Establishes Plan for Biomarker Study - MONTVALE, N.J., Feb. 19 /PRNewswire-FirstCall/ -- Memory Pharmaceuticals Corp. (Nasdaq: MEMY ) today announced that it plans to conduct a clinical study of MEM 3454, the Company's lead nicotinic alpha-7 partial agonist, on two biomarker...

Memory Pharmaceuticals Announces Results for Phase 2a Trial of MEM 1003 in Alzheimer's Disease

-Company to Host Conference Call at 9:00 a.m. EDT- MONTVALE, N.J., Oct. 15 /PRNewswire-FirstCall/ -- Memory Pharmaceuticals Corp. (Nasdaq: MEMY ) today announced top-line data from the multi-center, randomized, double-blind, placebo-controlled Phase 2a study of MEM 1003, a neuronal...

Memory Pharmaceuticals Highlights Progress with Key Programs at its R&D Day

...munity. The Company reported new clinical data for mem 1414, its lead PDE4 inhibitor, demonstrating the c... in humans. In addition, the Company has nominated mem 68626 as the lead development candidate from its 5...r, we are pleased to report that we have nominated mem 68626 as the lead compound in our 5-HT6 antagonist...

Memory Pharmaceuticals Reports Fourth Quarter and Full Year 2007 Financial Results

...ths, highlighted by our positive Phase 2a data for mem 3454 in Alzheimer's disease, the expansion of our schizophrenia development program for mem 3454 with our partner Roche, and the completion of...4996/MEM 63908, and initiate a biomarker study for mem 3454 in schizophrenia." Financial Results For ...
MEM in Biological Technology

Memory Pharmaceuticals Initiates Phase 2a Trial of MEM 3454 in Cognitive Impairment Associated with Schizophrenia

MONTVALE, N.J., Dec. 20 /PRNewswire-FirstCall/ -- Memory Pharmaceuticals Corp. (Nasdaq: MEMY ) today announced dosing of the first subject in a randomized, double-blind, placebo-controlled Phase 2a clinical trial of MEM 3454, the Company's lead nicotinic alpha-7 receptor partial agonist, in c...

Double Helix Strengthens its Strategic Pricing and Reimbursement Practice with Hire of Caryn Zieses

... previous client services experience in the Equity Research division of Lehman Brothers. Caryn holds an MBA from the Kellogg School of Management, an mem from Northwestern University, and a BSE in Chemical Engineering from the University of Pennsylvania. http://www.doublehelixdevelopment.c...

Memory Pharmaceuticals Reports Third Quarter 2008 Financial Results

...E10 inhibitor program and from SMRI related to the mem 1003 program which were recognized in 2007 but not...administrative costs and costs associated with the mem 1003 program. General and administrative expense...ory Pharmaceuticals presented preclinical data for mem 68626, its lead 5-HT6 antagonist, in a poster pres...

Memory Pharmaceuticals Reports First Quarter 2008 Financial Results

...nd our Phase 1 program for R4996/MEM 63908, initiating a Phase 2a trial for mem 1414, and advancing our 5-HT6 antagonist program into the clinic." Financ... $3.4 million decrease in costs associated with the clinical development of mem 1003. General and administrative expenses for the quarter ended March 31,...

Memory Pharmaceuticals Refocuses to Advance Development and Clinical Programs

...lpha-7 Receptor Agonist Collaboration with Roche. mem 3454, the lead compound in the Company's ni...y expects to initiate a biomarker study for mem 3454 in schizophrenia this summer, with res...expects to complete its Phase 1 program for mem 63908 and report top-line results in the fourth qu...

Neurobiological Technologies Announces Pricing of Its $60 Million Common Stock Offering

...will receive approximately $55 million of net offering proceeds, after underwriting discounts and estimated costs. Merriman Curhan Ford & Co. (Amex: mem ) acted as the sole book-running manager in this offering, and Dawson James Securities, Inc. acted as co-manager. Copies of the final prospectus may ...

Agendia BV Appoints Clinical and Scientific Advisory Board

...esearch programs and provide critical evaluations from academic and clinical perspectives. Agendia welcomes: Piet Borst (chair), M.D., PhD, CBE, For mem RS, Staff Member and Emeritus Director of the Netherlands Cancer Institute and Professor of Clinical Biochemistry, Amsterdam, The Netherlands Jose Ba...

Bionovo Announces Proposed Public Offering of Common Stock

...al Markets Corp. and Canaccord Adams Inc. are acting as joint book-running managers for the proposed offering, with Merriman Curhan Ford & Co. (Amex: mem ) acting as a co-manager. This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sal...

Screening for β2-adrenergic receptor agonists using the pH-sensitive dye,CypHer5, and the IN Cell Analyzer 3000

... LOPAC (Sigma)

Culture medium: mem (Sigma) containing 10% (v/v) FBS, 200 µ g/ml G418, L-glutamine, non-essential amino acids

Assay medium: mem (Sigma)

Agonist: Isoproterenol (Sigma) ...

The use of CypHer5E and the IN Cell Analyzer 1000 for live-cell receptor internalization studies

...EK293 cell line expressing EGF receptor HEK Culture medium: mem (Sigma M2279) containing: 10% (v/v) FBS Geneticin G418...

4. Replace the culture medium with 100 µl/well of fresh mem (phenol red free) containing 2.5–5 µg/ml CypHer5E anti-VSV-G an...

More>>

Other Tags
(Date:12/17/2014)... -- Expectant parents should leave prenatal picture-taking to medical ... Use of ultrasound imaging and heartbeat monitors to get ... agency warns. "Although there is a lack ... and heartbeat monitors, prudent use of these devices by ... FDA biomedical engineer, said in an agency news release. ...
(Date:12/17/2014)... HealthDay Reporter , TUESDAY, Dec. 16, ... America, and work commitment is a big reason why, new ... said Dr. Mathias Basner, an assistant professor of sleep and ... of Medicine. A time-use survey of nearly 125,000 Americans, ... main activity exchanged for sleep. Short sleepers -- those who ...
(Date:12/15/2014)... 15, 2014 South Florida’s leading urgent care ... can be a daze of hassle, hustle, and bustle that ... decking halls, to burns when making special meals and heartburn ... can happen at any time. To prevent this season of ... made a list of helpful and healthful holiday tips to ...
(Date:12/15/2014)... News) -- Expert pilots process visual information more efficiently ... better decisions during landings, a new study shows. ... pilots to master, and 36 percent of all airplane ... final approach and landing. Researchers monitored the brain ... pilots while they were at the controls of a ...
(Date:12/15/2014)... 15, 2014 At the leading, long-established ... AutismOne and Focus Autism will welcome ... research on the effects of toxins to children’s health, ... information. , Luminaries such as Dr. Lucija Tomljenovic ... with esteemed, credentialed colleagues of the United States to ...
Breaking Medicine News(10 mins):Health News:FDA Warns Against Fetal 'Keepsake' Videos 2Health News:Work Steals Valuable Sleep Time, Study Finds 2Health News:Work Steals Valuable Sleep Time, Study Finds 3Health News:MD Now Urgent Care Presents Healthy Holiday Tips 2Health News:MD Now Urgent Care Presents Healthy Holiday Tips 3Health News:Study Shows Why Expert Pilots Are Experts 2Health News:AutismOne and Focus Autism Collaborate on Scientific Conference; International Group of Researchers to Present in Chicago, May 2015 2Health News:AutismOne and Focus Autism Collaborate on Scientific Conference; International Group of Researchers to Present in Chicago, May 2015 3
(Date:12/17/2014)... 2014  Automation is fundamentally transforming the travel ... at international borders. Over the past decade, ePassports, ... veteran travelers to self process through border control ... at an increasing number of airports, seaports, and ... According to Maxine Most , Principal at ...
(Date:12/11/2014)... WINSTON SALEM, N.C. , Dec. 10, 2014  That ... known for quite a while. Hypertension – the medical term ... disease in the early 1800s, and the inflatable cuff that,s ... That doesn,t, however, mean there,s nothing new about hypertension, ... punctured some long-held beliefs about the condition and the best ...
(Date:12/10/2014)... N.C. , Dec. 9, 2014  Wake Forest Baptist ... education building for its School of Medicine. Funding for ... larger capital campaign that will be publicly launched next ... be located in the former 60 series R.J. Reynolds ... Innovation Quarter. Construction will begin immediately with plans to ...
Breaking Biology News(10 mins):Automated Border Control (ABC) Transforms the Global Travel Experience With More Than 2500 ABC eGates and APC Kiosks Deployed In Airports, Seaports, and Land Borders Worldwide 2Research points to need for new approaches to treatment of high blood pressure 2Research points to need for new approaches to treatment of high blood pressure 3Research points to need for new approaches to treatment of high blood pressure 4Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 2Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 3Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 4
Other Contents